Treatment and outcome of CPD-associated peritonitis 英文参考文献.docVIP

Annals of Clinical Microbiology and Antimicrobials BioMedCentral Review Open Access Treatment and outcome of CPD-associated peritonitis Laura Troidle and Fred Finkelstein* Address: New Haven CAPD, Renal Research Institute, New Haven, Connecticut, USA Email: Laura Troidle - kltroidle@; Fred Finkelstein* - fof@ * Corresponding author Published: 06 April 2006 Received: 19 January 2006 Accepted: 06 April 2006 Annals of Clinical Microbiology and Antimicrobials2006, 5:6 doi:10.1186/1476-0711-5-6 This article is available from: /content/5/1/6 ? 2006Troidle and Finkelstein; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract CPD-associated peritonitis is a leading cause of morbidity and mortality for ESRD patients maintained on CPD therapy. The percentage of ESRD patients maintained on CPD therapy is declining. The reasons are unclear, but may be due to concerns about CPD-associated peritonitis. The incidence of CPD-associated peritonitis has decreased largely attributed to technical advances and the identification of risk factors including exit-site infection, colonization with Staphylococcus aureus and depression. The typical spectrum of organisms causing peritonitis include gram-positive organisms (67%), gram- negative organisms (28%), fungi (2.5%) or anaerobic organisms (2.5%). Culture-negative episodes do occur: up to 20% of the episodes of peritonitis in some series are culture-negative. The treatment of CPD associated peritonitis is rather standardized with current recommendations by the International Society of Peritoneal Dialysis universally adopted. Approximately 80% of the patients developing peritonitis will respond to antimicrobial therapy and remain on